C ambridge-based Alnylam Pharmaceuticals said today it has earned a development milestone payment from GlaxoSmithKline totaling $3.2 million. Company officials said the payment is related to progress in the companies' collaboration on the use of VaxiRNA technology for the production of GSK influenza...
FULL ARTICLE AT Boston Herald